Findings may provide reassurance to patients with early-stage disease that surgery may help improve survival rates.
|Articles|February 1, 1995
Oncology NEWS International
- Oncology NEWS International Vol 4 No 2
- Volume 4
- Issue 2
NIH's Special Pooled Fund Includes NCI 'Donation' but No NCI Projects
BETHESDA, Md--Dr. Harold Varmus, director of the National Institutes of Health, has pooled $13.4 million from the budgets of all of the institutes to fund projects at five of them.
Advertisement
BETHESDA, Md--Dr. Harold Varmus, director of the National Institutesof Health, has pooled $13.4 million from the budgets of all ofthe institutes to fund projects at five of them.
The National Cancer Institute's "donated" share was$2.6 million. This money has to be considered lost because theNCI will not receive any money from the pooled funds
Articles in this issue
almost 32 years ago
FTC Advised to List Tar and Nicotine Levels Directly on Cigarette Packagesalmost 32 years ago
Multidisciplinary Approach Urged For Pain Reliefalmost 32 years ago
FDA Approves New Indication for Neupogen: Chronic Neutropeniaalmost 32 years ago
Department of Labor Wants to Study Possible Occupation-Cancer Linksalmost 32 years ago
Navelbine Is Now Available for Use in Inoperable Advanced Stage NSCLCalmost 32 years ago
ASH Panel: How Many Hemotologists/Oncologists Are Enough?almost 32 years ago
Mammography Van Brings Breast Cancer Screening to the Workplacealmost 32 years ago
FDA to Build $600 Million Campusalmost 32 years ago
Finasteride Studied as Prostate Ca PreventiveAdvertisement
Related to this article
In a retrospective study, high AI-derived whole-body tumor volume on PSMA PET-CT was associated with a 3.20-fold higher risk of death in prostate cancer.
The FDA set a June 15, 2027, target action date for sacituzumab tirumotecan in endometrial cancer previously treated with platinum chemotherapy and immunotherapy.
Parul N. Barry, MD, FACRO, discussed building programs early in a career and used low-dose radiotherapy and aromatase inhibitor tolerance to show how to demonstrate value.
Sunnie Kim, MD, outlined how she monitors for endocrine, renal, pulmonary, and other immune-related adverse events during adjuvant durvalumab.
Rocbrutinib plus R-CHOP yielded a 100% ORR and an 86.7% CR rate in 15 patients with untreated non-GCB DLBCL, warranting randomized evaluation.
Parul N. Barry, MD, FACRO, discussed extending advanced radiation services to satellite sites and offered guidance for early career physicians building new programs.
Rutika Mehta, MD, MPH, shares her framework for growth factor support, global dose reductions, and dropping agents during FLOT therapy.
Advertisement
Advertisement
Trending on CancerNetwork
1
KITE-753 Trials in R/R DLBCL Placed on Partial Clinical Hold for ICANS
2
Flood-Damaged Plant May Prolong US Chemotherapy Shortages to 2028
3
Managing FLOT Toxicity With Dose Reductions in Gastroesophageal Cancer
4
How Could Rocbrutinib Plus R-CHOP Reshape Frontline Non-GCB DLBCL Treatment?
5